LoginRegister
    Merck Keytruda, chemotherapy combination shows mixed results in phase 3 trial for lung cancerMerck Keytruda, chemotherapy combination shows mixed results in phase 3 trial for lung cancer
    Drug developers including AstraZeneca, GSK take fresh aim at guided-missile cancer drugs: ReportDrug developers including AstraZeneca, GSK take fresh aim at guided-missile cancer drugs: Report
    Biocon sells 2.44 pc stake in Biocon Biologics worth Rs 536.25 crore to True NorthBiocon sells 2.44 pc stake in Biocon Biologics worth Rs 536.25 crore to True North
    Sun Pharma plea to refix price of Ciprofloxacin Hydrochloride Injection rejectedSun Pharma plea to refix price of Ciprofloxacin Hydrochloride Injection rejected
    GPT Pharma Hyderabad unit red-flagged by USFDA for CGMP violationsGPT Pharma Hyderabad unit red-flagged by USFDA for CGMP violations
    Boehringer unveils DiaTEC, a new, proprietary purification technology for PCV2 vaccine Ingelvac CircoFLEXBoehringer unveils DiaTEC, a new, proprietary purification technology for PCV2 vaccine Ingelvac...
    Pulmatrix enters kinase inhibitor licensing pact with Lung Cancer Initiative at JnJPulmatrix enters kinase inhibitor licensing pact with Lung Cancer Initiative at JnJ
    Biostage provides update on USFDA investigational NDA for Cellspan Esophageal ImplantBiostage provides update on USFDA investigational NDA for Cellspan Esophageal Implant
    Mumbai police to like move against Johnson and Johnson over faulty hip implants, says reportMumbai police to like move against Johnson and Johnson over faulty hip implants, says report
    WuXi STA Pharma opens oligonucleotide API manufacturing facility in ChinaWuXi STA Pharma opens oligonucleotide API manufacturing facility in China
    Amgen, BeiGene collaborate to expand oncology presence in ChinaAmgen, BeiGene collaborate to expand oncology presence in China
    Antabio gets USD 4.4 million funding to develop new treatment for Pseudomonas aeruginosa infections in CF patientsAntabio gets USD 4.4 million funding to develop new treatment for Pseudomonas aeruginosa infections...
    Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

    Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

    © 2025 - Medical Dialogues. All Rights Reserved.
    Powered By: Hocalwire
    X